Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

OTCQB:NWBO - Post by User

Northwest Biotherapeutics Inc

Bullboard Posts

Post by pericles1on Sep 18, 2015 4:43pm

382 Views

Post# 24117212

Very Unhappy!!

Sold More today, what can I say. Enrollment is suspended and we are not sure why because the company will not tell us. German program seems to me to dead in the water. Phase II Direct is taking forever. The only positive I see is we still have our sugar daddy Woodford but that's not enough for me. Will continue to follow the stock and I'm sure their will be time to increase my position when the picture becomes clearer.

Bullboard Posts

AI companies to invest in